Molecular subtyping plays a critical role in guiding combination therapy, as evidenced by the use of Trastuzumab combined with chemotherapy as the standard treatment for HER2-positive gastric cancer, as well as emerging strategies targeting BRAF mutations, KRAS mutations, and MSI-H/dMMR status [462, 463]. Here, KRAS is linked to gastric cancer.